PET/DW-MRI for evaluating treatment in chronic hepatitis C patients.

Autor: Petersen RJ; Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen Denmark., Nielsen NS; Department of Infectious Diseases, Rigshospitalet, University of Copenhagen Denmark., Johannesen HH; Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen Denmark., Hansen AE; Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen Denmark., Jespersen S; Department of Infectious Diseases, Rigshospitalet, University of Copenhagen Denmark., Arnbjerg CJ; Department of Infectious Diseases, Rigshospitalet, University of Copenhagen Denmark., Löfgren J; Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen Denmark., Kjær MS; Department of Hepatology, Rigshospitalet, University of Copenhagen Denmark., Clausen MR; Department of Hepatology, Rigshospitalet, University of Copenhagen Denmark., Kjær A; Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen Denmark., Nielsen SD; Department of Infectious Diseases, Rigshospitalet, University of Copenhagen Denmark., Fischer BM; Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen Denmark.; PET Centre, School of Biomedical Engineering and Imaging Sciences, Kings College London, St Thomas' Hospital Westminster Bridge Road, London, UK.
Jazyk: angličtina
Zdroj: American journal of nuclear medicine and molecular imaging [Am J Nucl Med Mol Imaging] 2019 Feb 15; Vol. 9 (1), pp. 84-92. Date of Electronic Publication: 2019 Feb 15 (Print Publication: 2019).
Abstrakt: This feasibility study set out to investigate the use of FDG-PET/DW-MRI in chronic hepatitis C patients to examine changes in local liver inflammation after treatment with direct-acting antivirals (DAA). Twelve patients with chronic hepatitis C were prospectively enrolled, performing FDG-PET/DW-MRI prior to and after DAA treatment. PET/DW-MRI included PET acquisition 60 and 90 min after FDG-injection, DIXON, for attenuation correction, T2- and DW-MRI with 10 b-values between 0-700 s/mm 2 . The following parameters were measured from fusion of 3 volumes of interest (VOIs) placed in the liver parenchyma: Mean standard uptake value after 60 and 90 minutes (SUV mean60 and SUV mean90 ), total Apparent Diffusion Coefficient (ADC), perfusion fraction (PF), pseudo-diffusion (D*) and perfusion-free diffusion (D). We found PET/DW-MRI of chronic hepatitis C patients to be feasible. Patients were cooperative, tolerated the scans well and the image quality was acceptable. A total of 10 patients were available for final analysis. All patients achieved sustained virologic response and normalized alanine -aminotransferase (ALAT) levels after treatment with DAA. Perfusion fraction measured by DW-MRI changed significantly after treatment, from mean 0.21 (± 0.04) to 0.26 (± 0.06), P=0.005 and D* from 0.50 (± 0.13) × 10 -3 s/mm 2 to 0.62 (± 0.15) × 10 -3 s/mm 2 , P=0.028. All other parameters, including FDG-uptake, was unchanged. These results suggest that liver perfusion is changed shortly after DAA treatment, with no significant change in inflammation. The study concludes that PET/DW-MR is feasible in quantifying perfusion and possibly inflammation in chronic hepatitis C patients and may be used to follow treatment.
Competing Interests: None.
Databáze: MEDLINE
Externí odkaz: